West Pharmaceutical opens the week with clear analyst consensus, shares hold near recent highs

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 09:13.

West Pharmaceutical Services (US9523901012) starts the new week on the NYSE with a robust post-earnings backdrop and a clear consensus view from Wall Street analysts. The stock last closed at 329.52 dollars on 22 April after regular trading, while extended trading showed 328.25 dollars according to MarketBeat data.

What recent earnings show

On 23 April 2026, West Pharmaceutical reported first-quarter 2026 earnings per share of 2.13 dollars, beating analysts' consensus expectations of 1.68 dollars by 0.45 dollars, as compiled by MarketBeat. This marked a meaningful positive surprise for a company often treated as a defensive healthcare holding. MarketBeat's earnings summary for West Pharmaceutical

Revenues for the quarter were reported at around 795 million dollars, reflecting solid demand in injectable drug packaging and delivery components, per the same earnings overview. The strong beat on EPS versus consensus underpins the view that the company is executing well despite normalization effects after pandemic-related inventory adjustments.

Analyst views and consensus today

Analysts following West Pharmaceutical generally categorize the stock as a quality compounder within the global injectable drug packaging and delivery sector. Bitget notes that roughly 60 percent of around 15 tracked analysts rate the shares as Buy or equivalent, while about 40 percent sit at Hold or Neutral, with very few explicit Sell calls. Bitget overview of West Pharmaceutical analyst perspectives

The same compilation references a 12-month average target price range between roughly 365 and 380 dollars, suggesting room above the latest quoted levels near 330 dollars in late April 2026. Some more optimistic houses, including Jefferies in prior updates, have mentioned targets closer to 415 dollars, driven by expectations of faster margin improvements in high-value proprietary products.

The business behind the stock

West Pharmaceutical’s core business is providing packaging and delivery components for injectable medicines, including elastomer stoppers, seals and proprietary drug delivery systems for biologics and vaccines. Analysts highlight the company’s shift toward high-value products that support complex biologic formulations and its role in the supply chain for GLP-1-based weight-loss drugs, which are driving structural demand.

Where the shares trade today

The West Pharmaceutical shares (US9523901012) last traded on the NYSE at 329.52 dollars as of 2026-04-22, 15:59 Eastern, with extended trading at 328.25 dollars later that day, according to MarketBeat. This places the equity close to the consensus target corridor referenced by several Wall Street analysts.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Figures and dates are based on sources cited and may change. Retail investors should conduct their own research or consult a professional advisor before making investment decisions.